<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275298</url>
  </required_header>
  <id_info>
    <org_study_id>ESMEOVR</org_study_id>
    <nct_id>NCT03275298</nct_id>
  </id_info>
  <brief_title>Evolution of the Therapeutic Care in Ovarian Cancer From 2011</brief_title>
  <acronym>ESME-OVR</acronym>
  <official_title>Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform : Evolution of the Therapeutic Care in Ovarian Cancer Across the French Comprehensive Cancer Centers From 2011</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ESME OVR Data Platform is a multi-center real life database using a retrospective data&#xD;
      collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This&#xD;
      database compiles data from Patient's Electronic medical records (EMR), inpatient&#xD;
      Hospitalisation records and Pharmacy records.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This database compiles data from Patient's Electronic medical records (EMR), inpatient&#xD;
      Hospitalisation records and Pharmacy records.&#xD;
&#xD;
      Patient Database: Patient-related data integrates data from non-structured sources&#xD;
      (electronic medical records), such as patient medical records and reports of multidiscipline&#xD;
      team meetings. It can provide information on patient demographics, primitive tumour,&#xD;
      relapses, pathology reports, metastatic disease, therapeutic care/settings and withdrawal&#xD;
      reasons when applicable, and clinical events.&#xD;
&#xD;
      Treatment Database: Pharmacy records-related data is a structured database including all data&#xD;
      pertaining to medications prescribed and dispensed by pharmacies within each FCCC,&#xD;
      specifically chemotherapy and co-prescriptions. It does not contain information on products&#xD;
      that are prescribed or delivered outside of the center. From each center's pharmacy database,&#xD;
      information on systemic treatment patterns (dates, pharmaceutical forms, treatment protocols,&#xD;
      etc.) can be obtained.&#xD;
&#xD;
      Hospitalisation Database: Hospitalisation-related data is a structured and systematic&#xD;
      database that contains all medical data reported related to any hospitalisation in the FCCC,&#xD;
      and is used to bill the French National Health Insurance Fund (Assurance Maladie). It&#xD;
      provides information on patient entry and discharge dates as well as diagnostic and&#xD;
      therapeutic procedures performed, including radiotherapy and surgery.&#xD;
&#xD;
      Data imported into the final database are controlled, recoded, and harmonized before import&#xD;
      according to a data management plan. All coding procedures are predefined by the data&#xD;
      manager. There is no transmission of individual data; all data are centralized within each&#xD;
      center using a shared anonymous format. All data are exclusively obtained retrospectively; no&#xD;
      attempts are made to recover non available data from the patient's medical record by&#xD;
      contacting healthcare providers or patients.&#xD;
&#xD;
      ESME OVR Data Platform aims to be a clinical and therapeutic database centralising existing&#xD;
      and available data from different sources used in the FCCCs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the evolution of therapeutic care in ovarian cancer across the French comprehensive cancer centers</measure>
    <time_frame>baseline</time_frame>
    <description>Patient characteristics, tumor characteristics and treatment patterns</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the impact of therapeutic strategies on survival criteria</measure>
    <time_frame>From date of diagnosis or first treatment until the date of date of death from any cause. Follow up until 2022.</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Describe the impact of therapeutic strategies on survival criteria</measure>
    <time_frame>From date of diagnosis or first treatment until the date of first documented progression or date of death from any cause. Follow up until 2022.</time_frame>
    <description>Progression free survival</description>
  </other_outcome>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive females treated for an ovarian cancer in a French Comprehensive Cancer&#xD;
        Center over the selection period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  18 years old female&#xD;
&#xD;
          -  Female receiving surgery, chemotherapy, targeted therapy, immunotherapy, radiation&#xD;
             therapy, diagnostic procedure, other specific therapeutic procedure) in a French&#xD;
             Comprehensive Cancer Center.&#xD;
&#xD;
        Exclusion criteria : None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Laure Martin, MD, PhD</last_name>
    <phone>+ 33 1 44 23 55 56</phone>
    <email>al-martin@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gaëtane Simon, Msc</last_name>
    <phone>+33 1 73 79 73 00</phone>
    <email>g-simon@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BOCQUET</last_name>
      <phone>+33 2 40 67 98 86</phone>
      <email>francois.bocquet@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne JAFFRE</last_name>
      <phone>+33 5 56 33 78 48</phone>
      <email>a.jaffre@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Valérie GUIZARD</last_name>
      <phone>+33 2 31 45 52 45</phone>
      <email>av.guizard@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MOURET-REYNIER</last_name>
      <phone>+33 4 73 27 81 37</phone>
      <email>marie-ange.mouret-reynier@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine DABAKUYO</last_name>
      <phone>+33 3 45 34 80 67</phone>
      <email>sdabakuyo@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Paule LEBITASY</last_name>
      <phone>03 20 29 55 60</phone>
      <email>m-lebitasy@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas BACHELOT</last_name>
      <phone>+33 4 78 78 26 54</phone>
      <email>thomas.bachelot@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilian LABORDE</last_name>
      <phone>+33 4 91 22 35 10</phone>
      <email>LABORDEL@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer Montpellier / Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie DELAINE</last_name>
      <phone>+33 4 67 61 47 39</phone>
      <email>Stephanie.delaine@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Aude HERMAN</last_name>
      <phone>+33 3 83 59 86 68</phone>
      <email>m.herman@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BOCQUET</last_name>
      <phone>+33 2 40 67 98 86</phone>
      <email>francois.bocquet@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel CHAMOREY</last_name>
      <phone>+33 4 92 03 15 29</phone>
      <email>emmanuel.chamorey@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne BRAIN</last_name>
      <email>etienne.brain@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien PARENT</last_name>
      <phone>+33 3 26 50 42 76</phone>
      <email>damien.parent@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias BRETON</last_name>
      <phone>+33 2 99 25 32 67</phone>
      <email>m.breton@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès LOEB</last_name>
      <phone>+33 2 32 08 22 80</phone>
      <email>agnes.loeb@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne BRAIN</last_name>
      <phone>+33 1 47 11 15 15</phone>
      <email>etienne.brain@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel VELTEN</last_name>
      <phone>+33 3 88 25 24 53</phone>
      <email>mvelten@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine BERCHERY</last_name>
      <phone>05 31 15 50 60</phone>
      <email>Berchery.Delphine@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie DEJEAN</last_name>
      <phone>+33 1 42 11 46 49</phone>
      <email>valerie.dejean@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Romeo, C, P Meeus, M Rodrigues, E Leblanc, A Floquet, P Pautier, F Marchal, et al. &quot; EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment &quot;. In ePoster, A513.3-A513. BMJ Publishing Group Ltd, 2019. https://doi.org/10.1136/ijgc-2019-ESGO.1013.</citation>
  </results_reference>
  <results_reference>
    <citation>De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecol Oncol. 2021 Oct;163(1):64-71. doi: 10.1016/j.ygyno.2021.07.019. Epub 2021 Jul 19.</citation>
    <PMID>34294414</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodrigues M, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Provensal Gross M, Leblac E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Courtinard C, Gladieff L. Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France. ESMO Congress, September 16-21, 2021 [ePoster 746P] DOI:https://doi.org/10.1016/j.annonc.2021.08.1188</citation>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>observational study</keyword>
  <keyword>survival</keyword>
  <keyword>real world data</keyword>
  <keyword>real life setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

